S100A8 and rheumatoid arthritis: Moreover, molecular docking experiments demonstrated strong binding affinities between ABCC4, S100A8, ISG20, and methotrexate, as well as other drugs, suggesting that these biomarkers could be potential targets for the treatment of RA.